Mireille Sanders
Chief Operating Officer chez PHARMING GROUP N.V.
Fortune : 287 121 $ au 31/03/2024
Profil
Mireille Sanders is currently the Chief Operations Officer at Pharming Group NV.
Previously, she worked at Janssen Pharmaceuticals, Inc. as the Head-Clinical Supply Chain Strategic from 2016 to 2019.
Ms. Sanders is a graduate of Technische Universiteit Eindhoven.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PHARMING GROUP NV
0,04% | 31/03/2023 | 260 896 ( 0,04% ) | 287 121 $ | 31/03/2024 |
Postes actifs de Mireille Sanders
| Sociétés | Poste | Début |
|---|---|---|
| PHARMING GROUP N.V. | Chief Operating Officer | 15/12/2020 |
Anciens postes connus de Mireille Sanders
| Sociétés | Poste | Fin |
|---|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | 01/01/2019 |
Formation de Mireille Sanders
| Technische Universiteit Eindhoven | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHARMING GROUP N.V. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
